Market closedNon-fractional
CytomX/CTMX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About CytomX
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Ticker
CTMX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South San Francisco, United States
Employees
121
Website
www.cytomx.com
CytomX Metrics
BasicAdvanced
$111M
Market cap
6.68
P/E ratio
$0.21
EPS
1.08
Beta
-
Dividend rate
Price and volume
Market cap
$111M
Beta
1.08
Financial strength
Current ratio
1.157
Quick ratio
1.131
Long term debt to equity
-25.72
Total debt to equity
-40.631
Management effectiveness
Return on assets (TTM)
3.23%
Return on equity (TTM)
-27.95%
Valuation
Price to earnings (TTM)
6.678
Price to revenue (TTM)
0.926
Price to book
-3.05
Price to tangible book (TTM)
-2.9
Price to free cash flow (TTM)
-1.196
Growth
Revenue change (TTM)
76.24%
Earnings per share change (TTM)
-119.85%
3-year revenue growth (CAGR)
21.32%
3-year earnings per share growth (CAGR)
-44.06%
What the Analysts think about CytomX
Analyst Ratings
Majority rating from 7 analysts.
CytomX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$41M
55.64%
Net income
$14M
1,612.50%
Profit margin
33.09%
1,003.00%
CytomX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.02
$0.04
$0.01
$0.17
-
Expected
-$0.21
-$0.19
-$0.03
-$0.08
-$0.14
Surprise
-90.24%
-121.18%
-135.00%
-305.23%
-
CytomX News
AllArticlesVideos
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
GlobeNewsWire·1 month ago
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
GlobeNewsWire·1 month ago
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CytomX stock?
CytomX (CTMX) has a market cap of $111M as of July 27, 2024.
What is the P/E ratio for CytomX stock?
The price to earnings (P/E) ratio for CytomX (CTMX) stock is 6.68 as of July 27, 2024.
Does CytomX stock pay dividends?
No, CytomX (CTMX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next CytomX dividend payment date?
CytomX (CTMX) stock does not pay dividends to its shareholders.
What is the beta indicator for CytomX?
CytomX (CTMX) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell CytomX stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.